Don't hesitate to contact us. We are happy to answer your questions.
Committed to bringing innovative cancer treatments and regenerative therapies to patients worldwide
Innovation in cell and gene therapies
Committed to bringing innovative cancer treatments and regenerative therapies to patients worldwide
Miltenyi Biomedicine is a biopharmaceutical company whose mission is to bring accessible and innovative cancer treatments and regenerative therapies to patients.
We strive to make a difference for patients who fight serious diseases every day – to improve their quality of life and give them the chance to live fully and create new dreams.
Building on Miltenyi’s decades of experience, we are uniquely positioned to realize the great potential of the new cell and gene therapies and make them available to patients worldwide. Both Miltenyi Biomedicine and Miltenyi Biotec were founded and are privately owned by Stefan Miltenyi who is advancing cellular therapy since 1989.
Looking for an exciting new career challenge? Then join us in our mission to bring cancer and regenerative treatments to patients!
We are an international and interdisciplinary team of skilled professionals. Our medical staff consists of accomplished hematologists and oncologists expert in treating patients and able to develop new therapeutic options for them. They are at the forefront of clinical research, leading the design and execution of our clinical trials.
We are serious about safety and quality of life, and we hold ourselves accountable to our patients. A highly professional team for pharmacovigilance and regulatory – with a proven track record in bringing new medicines to approval – is in charge of ensuring the safety of our pharmacological developments at all stages.
As we develop innovative cancer treatments, we push ourselves to make a real difference in patients’ lives.
Our CliniMACS® Cell Factories comply with GMP regulations for manufacturing genetically engineered cellular products, and they are certified in the manufacturing permit issued by the local authorities. Our manufacturing process and facilities are inspected by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the German Paul Ehrlich-Institut (PEI).
Miltenyi Biomedicine’s leadership team
Our diverse management team – with backgrounds in medicine, industry and pharmacology – combines decades of experience in drug development, manufacturing and commercialization. The team is guiding the organization towards its goal of making a real difference in patients’ lives.
Toon Overstijns joined Miltenyi in 2017 and is member of the board of directors of Miltenyi Biotec and chairman of the Board of Miltenyi Biomedicine.
Before joining the company, Toon was more than 25 years at Janssen Pharmaceuticals (J&J) were he held different positions. He was responsible for managing the Global Infectious Diseases & Vaccines Therapeutic Area based in USA. Prior to that he was company president of Janssen Japan based in Tokyo and Managing Director Janssen Germany based in Neuss.
Toon served as Field Officer for UNICEF in Bangladesh and Ethiopia prior to joining the pharmaceutical industry.
Toon holds an MD degree as well as a Chemistry and MBA degree. He studied at the University of Leuven in Belgium, the University of Stellenbosch in South Africa and at Stanford University in California.
Norbert Hentschel joined Miltenyi in 2001 and is responsible for the global Finance, IT and Purchasing Organization.
He joined Miltenyi Biotec in 2001 from E.ON, where he served as an Expert in US Generally Accepted Accounting Principles. He started his Career in the Audit Division of Arthur Andersen, where he was involved in international IPOs, M&A Transactions, and year-end audits.
Norbert holds a Master’s degree in Economics (Dipl.-Volkswirt) from the University of Cologne. He has been a board member of the industry association BIO Deutschland since 2007, and he is co-editor of the Corporate Finance Magazine published by Handelsblatt Fachmedien.
Silke Holtkamp joined Miltenyi in 2009 and is leading the Clinical Development Department with all of the functions involved in Europe, which includes overseeing the Clinical Development strategy to support product approval with EMA as well as overseeing all clinical operational activities in Europe.
Silke has long-standing expertise in all aspects of clinical research, with medicinal products as well as medical devices, in a variety of companies. With more than 10 years of experience within the Miltenyi Group in different functions in Clinical Development, she has been successful in building, leading and re-structuring teams within this field.
Silke studied Biology and holds a Doctor of Natural Science (Dr.rer.nat) degree from Johannes Gutenberg University of Mainz, Germany.
Wing Leung joined Miltenyi in 2016 and is responsible for clinical development in the US and APAC.
Prior to joining the company, Wing built more than 30 years of experience in academia and industry. He has worked in companies and institutions such as Johns Hopkins University (Faculty Member), St. Jude Children’s Research Hospital (Faculty Member and Chairman), Miltenyi Biotec (VP of Clinical Development) and Miltenyi Biomedicine (Senior Scientific Advisor). His fields of expertise are Transplantation and Cellular Therapy, Immunobiology and Clinical Development.
Wing holds an MD degree from the University of Hong Kong and a PhD from Johns Hopkins University.
Linda Hanssens joined Miltenyi Biomedicine in 2019 and is responsible for developing the global medical strategy of the cell therapy portfolio, managing educational and scientific activities such as advisory boards and Investigator Initiated Trials (IITs) as well as supervising the Medical Science Liaisons (MSLs).
Linda has built solid experience in medical affairs and clinical development in several large pharmaceutical companies such as UCB, BMS and GSK.
Linda received her Doctorate in Medical Sciences and a postgraduate degree in Public Health Sciences from the University of Liege, Belgium. She holds a Master’s degree in Molecular Biology from the University of Louvain, Belgium.
Christoph Coch joined Miltenyi Biomedicine in 2019 and is responsible for developing and managing all research needed to translate the most promising projects from basic research into early clinical trials to demonstrate safety and a first proof of concept in healthy volunteers and/or patients.
Before joining the company, Christoph was a member of the executive board of the German Academic Network of Coordinating Centres of Clinical Trials (KKS-Netzwerk). Christoph has experience in basic, preclinical and clinical research. As head of the Clinical Study Core Unit of the University Hospital Bonn, he supported the planning and conduct of numerous investigator-initiated clinical trials of all phases and legal backgrounds. As head of the Phase I Unit of the University Bonn, he was involved in Phase I clinical trials as an investigator.
Christoph received his MD degree from the Albert Ludwig University of Freiburg, Germany. He is a member of the expert group supporting the executive board of the Association for Applied Human Pharmacology (AGAH), the medical society for Clinical Pharmacology.
Dirk Winnemöller joined Miltenyi Biomedicine in 2019 and is responsible for managing all commercial functions, including business development, market access and marketing. He also provides support setting up and expanding the Miltenyi Biomedicine Organization.
Dirk has more than 12 years of experience within the Miltenyi Group in different commercial and general management roles, including the general management of Miltenyi Biotec subsidiaries in Australia, Germany, Austria and Switzerland. He has led several diverse teams and has proven to be successful in building, leading and restructuring commercial organizations.
Dirk studied Biology at the Julius Maximilian University of Würzburg and received a Doctorate in Biology / Natural Sciences from the Institute for Reconstructive Neurobiology at the University of Bonn, Germany.
Dr. Jasna Ribaric joined Miltenyi Biomedicine in 2019 and is responsible for leading and managing all clinical requirements regarding patient safety and global pharmacovigilance.
Before entering the company, Jasna held various R&D and Pharmacovigilance positions of growing responsibility at mid-size international companies and large pharmaceutical companies, including: Johnson & Johnson’s Ethicon Endo-Surgery Europe Gmbh; International Clinical Research Organization ‘Clinipace’, USA; and French CRO ‘Medextens’. She has served as Safety Physician, Medical Monitor, Medical Advisor and Clinical Consultant.
Jasna received her MD degree from the Faculty of Medicine, University of Zagreb, Croatia, and was employed at the Croatian Ministry of Health and Public Health Institute in Zagreb, Croatia.
Michael Jandke joined Miltenyi Biomedicine in 2019 and is responsible for Regulatory Affairs globally.
Prior to joining the company, Michael worked for several generic pharmaceutical companies. He then worked in various positions in several innovative healthcare companies, covering areas such as somatic Cell Based Medicinal Products (sCBMP), Tissue Engineered Products (TEP), and Gene Therapeutics.
Michael studied Pharmacy at Humboldt University in Berlin, Germany, where he received his Doctorate in the area of Molecular Medicine.
Barbara Philippe joined Miltenyi Biomedicine in 2020 and is responsible for implementing the Manufacturing and Supply Chain Strategy, leading the CAR-T cells manufacturing sites in Germany and the USA, and leading the CDMO organization.
Barbara joined the company from GSK, where she had a long-standing career of 20 years in manufacturing, taking up several roles with increasing responsibilities. She is experienced in setting up and leading large manufacturing plants and making strategic development plans.
Barbara holds a PhD degree in Medical Biology from the Université Catholique de Louvain in Brussels, a Master’s degree in Technical Biomedical Science from the Université Catholique de Louvain in Brussels, and a Master’s degree in EPM (Entreprise Perfectionnement Management).